The European Chemicals Agency (ECHA) is consulting on the availability of substitutes and alternatives to 3-iodo-2-propynylbutylcarbamate (IPBC)
The EU Biocidal Products Regulation (EU BPR) applies in NI.
If an active substance meets the substitution criteria set out in Article 10(1), it will be considered as a candidate for substitution. This means that the supply and use of biocidal products containing candidates for substitution must be prohibited or restricted under EU BPR, unless all the following conditions can be shown:
for the uses specified for that product, there are no other authorised biocidal products or existing non-chemical control or prevention methods that: present a significantly lower overall risk for human health, animal health and the environment are sufficiently effective present no other significant economic or practical disadvantages the chemical diversity of the available active substances is not adequate to minimise the occurrence of resistance in the target harmful organism. Â The following active substance has been identified as a potential candidate for substitution under EU BPR and ECHA has launched a public consultation to collect information on the availability of substitutes and alternatives, running until the stated date:
3-iodo-2-propynylbutylcarbamate (IPBC) (CAS 55406-53-6 EC 259-627-5) in product type 8Â
6 November 2024 Â ECHA is consulting on the essentiality of medetomidine
If an active substance meets the exclusion criteria set out in Article 5(1), it would not normally be approved for use in biocidal products. However, a derogation would allow the active substance to be approved under Article 5(2) if one of the following criteria can be met:
exposure is negligible the active substance is essential to prevent a serious danger to human or animal health or the environment not approving the substance would have a disproportionate negative impact on society compared to the risks  The following active substance has been identified as meeting the exclusion criteria under EU BPR and ECHA has launched a public consultation to collect information on whether the conditions for derogation are satisfied, running until the stated date:
Medetomidine (CAS 86347-14-0 EC 811-718-6) in product type 21
6 November 2024 Â Comments on either of these consultations should be submitted to ECHA using the dedicated webforms. These consultations and their outcomes are not applicable under the GB Biocidal Products Regulations (GB BPR). | 